ProCE Banner Activity

Ponatinib Plus Hyper-CVAD Active as Frontline Therapy in Ph+ ALL

Slideset Download
Conference Coverage
In this phase II open-label study, the combination of ponatinib with hyper-CVAD resulted in high complete cytogenetic and molecular response rates in patients with Ph+ ALL.

Released: December 12, 2016

Expiration: December 11, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen